Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Introduction Publisher



Aghamir SMK1
Authors

Source: Liquid Biopsy in Urogenital Cancers and its Clinical Utility Published:2022


Abstract

Cancer is a critical public health issue globally and is known to be the second most common cause of death in North America [1]. Over all, it is estimated that about 600, 000 deaths occurred in the United States in 2020 due to cancers, and 1, 800, 000 Americans were diagnosed as new cancer cases in 2020 alone [1, 2]. © 2022 Elsevier Inc. All rights reserved.
Related Docs
View other Related Docs
1. Liquid Biopsy As a New Tool for Diagnosis, Monitoring, and Personalized Medicine in Urogenital Cancers, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
2. Overview of Liquid Biopsy, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
3. Liquid Biopsy in Female Genital Tract (Ovarian Cancer, Endometrial Tumor, and Cervical Tumor), Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
Experts (# of related papers)
View all Related Experts
Seyed Mohammad Kazem Aghamir Mohammad Ali (8)
Reza Malekzadeh (2)
Other Related Docs
4. Circulating Tumor Cells and Dnas in Prostate Tumors, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
5. The Global Burden of Cancer 2013, JAMA Oncology (2015)
6. Age Limit for Familial Prostate Cancer Screening, Caspian Journal of Internal Medicine (2025)
7. Global, Regional and National Burden of Cancers Attributable to High Fasting Plasma Glucose in 204 Countries and Territories, 1990-2019, Frontiers in Endocrinology (2022)
8. Liquid Biopsy in Bladder Tumors, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
9. Liquid Biopsy in Pediatric Urogenital Tumors, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
10. The Effect of Mesenchymal Stem Cells-Derived Exosomes on the Prostate, Bladder, and Renal Cancer Cell Lines, Scientific Reports (2022)
11. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 a Systematic Analysis for the Global Burden of Disease Study 2019, JAMA Oncology (2022)
12. Molecular Biology and Genetic Change Definition, (2024)
13. Mortality Rates and Years of Life Lost Due to Cancer in Iran: Analysis of Data From the National Death Registration System, 2016, International Journal of Cancer Management (2022)
14. The Lost Productivity Cost of Premature Mortality Owing to Cancers in Iran: Evidence From the Globocan 2012 to 2018 Estimates, Value in Health Regional Issues (2022)
15. Expected Years of Life Lost Due to Adult Cancer Mortality in Yazd (2004-2010), Asian Pacific Journal of Cancer Prevention (2016)
16. The Gene Manipulation and Cellular Immunotherapy Combination in the Treatment of Cancer, Iranian Journal of Biotechnology (2022)
17. Incidence, Mortality, and Epidemiological Aspects of Cancers in Iran; Differences With the World Data, Journal of B.U.ON. (2016)
18. The Global, Regional, and National Burden of Oesophageal Cancer and Its Attributable Risk Factors in 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet Gastroenterology and Hepatology (2020)
19. Years of Potential Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Iran, Asian Pacific Journal of Cancer Prevention (2015)
20. Liquid Biopsy in Kidney Tumor, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)